A065660 Stock Overview
A bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Anterogen.Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,000.00 |
| 52 Week High | ₩19,150.00 |
| 52 Week Low | ₩12,300.00 |
| Beta | 0.34 |
| 11 Month Change | 6.38% |
| 3 Month Change | -4.58% |
| 1 Year Change | 12.87% |
| 33 Year Change | -79.17% |
| 5 Year Change | -62.73% |
| Change since IPO | -61.64% |
Recent News & Updates
Shareholder Returns
| A065660 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 7.1% | 4.0% | 0.9% |
| 1Y | 12.9% | 49.5% | 3.8% |
Return vs Industry: A065660 underperformed the KR Biotechs industry which returned 49.5% over the past year.
Return vs Market: A065660 exceeded the KR Market which returned 3.8% over the past year.
Price Volatility
| A065660 volatility | |
|---|---|
| A065660 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A065660 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A065660's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Seong-Gu Lee | anterogen.com |
Anterogen Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension.
Anterogen.Co.,Ltd. Fundamentals Summary
| A065660 fundamental statistics | |
|---|---|
| Market cap | ₩145.97b |
| Earnings (TTM) | -₩2.31b |
| Revenue (TTM) | ₩6.66b |
21.9x
P/S Ratio-63.1x
P/E RatioIs A065660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A065660 income statement (TTM) | |
|---|---|
| Revenue | ₩6.66b |
| Cost of Revenue | ₩3.92b |
| Gross Profit | ₩2.74b |
| Other Expenses | ₩5.06b |
| Earnings | -₩2.31b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -237.78 |
| Gross Margin | 41.18% |
| Net Profit Margin | -34.75% |
| Debt/Equity Ratio | 0% |
How did A065660 perform over the long term?
See historical performance and comparison